Interim Statement on the First Three Months of Financial Year 2025Cohort 7 of the clinical trial of HDP-101 in multiple myeloma safe and well toleratedCohort 8 expected to start soonClinical ...

OXB Named Among UK’s Best Employers by Financial Times in 2025Oxford, UK – OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, has been honoured with a spot on the ...

Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patientsPrimary endpoint met, no drug-related serious adverse events Positive hematoma and edema ...

Syncona Limited Mosaic Therapeutics in-licences two clinical-stage assets from Astex Pharmaceuticals In-licensing these clinical-stage assets has significantly de-risked and accelerated Mosaic’s ...

NEW IQVIA INSTITUTE REPORT WARNS OF ACCESS DISPARITIES FOR CAR T-CELL THERAPY ACROSS EUROPE Stockley Park, UK – 23 April 2025 – A new report reveals disparities in chimeric antigen receptor (CAR) ...

Hikma reiterates full year guidance following good start to the year London, 24 April 2025 – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update ...

A New Movement Calls for Change Women are being overlooked in the UK’s HIV response and face multiple barriers to prevention, testing, and care.In England, HIV diagnoses among women who have sex with ...

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS Joenja® is the first and only medicine specifically for APDS to be reimbursed within the ...

Ingelheim, Germany and Amsterdam, the Netherlands, 23 April 2025 – Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches ...

Thermo Fisher Scientific Opens Advanced Therapies Collaboration Center in Greater San Diego to Help Accelerate Cell Therapy Development Innovative 6,000-square-foot facility enables clinical and ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

Debiopharm and Oncodesign Services Launch Strategic Collaboration to Propel Radiopharmaceuticals in Preclinical Research April 24th, 2025 Martigny, Switzerland. Dijon, France – Debiopharm Research & ...